Presentation is loading. Please wait.

Presentation is loading. Please wait.

6 th Science and Standards Symposium January 16 th, 2013 Istanbul, Turkey Quality Attributes of Monoclonal Antibodies Tina S. Morris, Ph.D., Vice President.

Similar presentations

Presentation on theme: "6 th Science and Standards Symposium January 16 th, 2013 Istanbul, Turkey Quality Attributes of Monoclonal Antibodies Tina S. Morris, Ph.D., Vice President."— Presentation transcript:

1 6 th Science and Standards Symposium January 16 th, 2013 Istanbul, Turkey Quality Attributes of Monoclonal Antibodies Tina S. Morris, Ph.D., Vice President Biologics & Biotechnology USP-NF

2 Quality Control for Biotechnology Products - ICH  ICH Guideline Q6B - Test Procedure and Acceptance Criteria for Biotechnology/ Biologic Products  Quality Attributes –Identity –Purity –Impurity profile –Potency –Strength –Safety

3 Q6B on Analytical Characterization

4 Product Type versus Molecule Class – Platform Accessibility Product TypeMolecule ClassSourceLegacy Products in this Class? Accessible to analytical platform approach? Cell TherapyWhole CellPatient-autologousNo Clotting FactorProtein/EnzymePlasma and recombinantYesto some extent Cytokine or growth factor Peptide or small protein Mostly recombinantYes - hormones Yes EnzymeProteinBoth recombinant and naturally derived Yes Monoclonal antibody Protein, IgG1RecombinantNoYes Polyclonal antibody Protein, Ig mixturePlasma-derivedYesto some extent ToxinProteinBoth recombinant and naturally derived Yes VaccineVariousBoth recombinant and naturally derived Yesto some extent Other – what about heparin? Polydisperse glycosaminoglycan Naturally derivedYes

5 Which Quality Attributes to Consider? Biological characteristicsPhysico-chemical characteristics Fab Fc Antigen binding Effector functions complement interaction Fc recepter interaction N-terminal heterogeneity pyroglutamate formation Other modifications AA modifications deamidation, oxidation, glycation, isomerization Fragmentation Cleavage in hinge region, Asp-Pro Oligosaccharides Fucosylation, sialyation, galactosylation… Disulfide bonds Free thiols, disulfide shuffling, thioether C-terminal heterogeneity Lysine processing, proline amidation

6 Monoclonal Antibodies and Platform Assays  Quality Control Assays for Monoclonal Antibodies  Product Class Analytical Methods - platform assays –Examples Size exclusion chromatography Isoelectric Focusing Oligosaccharide assay Peptide Mapping Process Related Impurity assays o Host cell protein o DNA o Protein A Compendial Assays; Endotoxin, pH, Conductivity, Sterility

7  Analytical Procedures for Recombinant Therapeutic Monoclonal Antibodies  Will contain a collection of validated compendial procedures with established system suitability criteria for therapeutic MAbs  Will be accompanied by USP MAb System Suitability RS  Will not contain product or class specific acceptance criteria  Will be supported by multiple >1000 Information Chapters that discuss quality attributes, manufacturing and quality control aspects for MAbs 7 Capturing Platform Assays in a Compendial Chapter

8  Product Scope:  Murine, chimeric, and humanized IgG isotype Mabs and subtypes (e.g. IgG1 and IgG2)  MAbs for therapeutic, prophylactic and in vitro diagnostic use  EXCLUDES: MAbs used as manufacturing reagents or process materials  Included Procedures:  Size Exclusion Chromatography (SEC)  Capillary SDS Electrophoresis (reduced and non-reduced)  Oligosacchride Analysis  Sialic Acid Analysis 8 Current Chapter Scope

9  Purpose:  Evaluate the proposed Size Variant and CE procedures  Test the proposed USP Monoclonal IgG system suitability standard  Gather batch data on MAbs currently made in commercial manufacturing as well as in development (clinical and non-clinical) Study Logistics and Time Line:  Study materials were dispatched in at the end of November, 2012, deadline for data submission is March 30 th, 2013  Large international study participation of 30 laboratories Chapter Time Line:  Will appear in PF39(3) with a comment deadline of July 31 st, 2013 9 Round Robin Study in Support of

10  Compendial use –Needed for system suitability for proposed SEC and CE-SDS USP procedures  Material Description and Source –IgG1 MAb –Lyophilization protocol available  Will be developed and distributed as a USP reference standard in lyophilized presentation USP Monoclonal IgG System Suitability Standard

11 SEC Profile of IgG System Suitability Standard

12 Antibody Glycosylation Analysis – fit for Common Assay(s)? Mab Glycan standard Glycans from polyclonal human IgG G2F+1 NeuAc Data courtesy of / expert panel CE Analysis of Released Oligosaccharides

13 Glycosylation and Bioactivity Correlation 00.511.52 Bioactivity Moles Galactose Mole Heavy Chain  galactosidase treated 50 100 150 200 Bioactivity 00.511.52 Bioactivity Correlates with Galactose Content

14 Galactosylation Profile of hIgG Glycans Fluorophore - HPLC HPAEC MS methods F-CE

15 Product-Specific Quality Attributes of MAbs Several Quality Attributes of MAbs can be highly product specific and should be addressed at the monograph level. Examples  Charge heterogeneity, analyzed by IEX chromatography or cIEF  Hydrophobic Interaction Chromatography  Ligand binding, e.g. by ELISA  Cell-based potency assay

16 Quality Control for Biotechnology Products 0 0.01 0.02 0.03 0.04 0.05 0.06 0.07 102030405060 mAu Time (min) 2 3 4 1 5 3a 2b 2a 1b 1a pE Peak 1 Q pE Peak 2 QpE Q Peak 4 Q pE Q Peak 5 Q pE Peak 3 pE Ion-Exchange Profile of an Intact Antibody

17 Quality Control for Biotechnology Products 0 20 40 60 80 100 01224364860 mAu Time (min) A B C D F G H I J K L M NO P E Ion-Exchange Profile of a Papain Digested Antibody + + Fc F(ab) Papain

18  Therapeutic Monoclonal Antibodies – General Considerations  Product Class Overview  General Manufacturing and Quality Considerations Analytical Control Strategies for Recombinant Monoclonal Antibodies  Quality Attributes, their determination, control and measurement  General considerations and analytical considerations for quality attributes that are product specific  Comparability and post-approval quality issues 18 Information Chapter(s) in Development

19  USP Monoclonal Antibody Expert Panel  Chair: Dr. Anthony Mire-Sluis  USP Biologics & Biotechnology Monographs 1 Expert Committee  Chair: Dr. Michael Mulkerrin  USP Staff  EC and EP Liaison: Dr. Anita Szajek  Reference Standard Scientist: Dale Schmidt 19 Acknowledgements

20 USP Headquarters, Rockville, Maryland



Download ppt "6 th Science and Standards Symposium January 16 th, 2013 Istanbul, Turkey Quality Attributes of Monoclonal Antibodies Tina S. Morris, Ph.D., Vice President."

Similar presentations

Ads by Google